TY - JOUR
T1 - Update Breast Cancer 2022 Part 6 - Advanced-Stage Breast Cancer
AU - Lüftner, Diana
AU - Lux, Michael P
AU - Fehm, Tanja N
AU - Welslau, Manfred
AU - Müller, Volkmar
AU - Schütz, Florian
AU - Fasching, Peter A
AU - Janni, Wolfgang
AU - Thomssen, Christoph
AU - Witzel, Isabell
AU - Beierlein, Milena
AU - Belleville, Erik
AU - Untch, Michael
AU - Thill, Marc
AU - Ditsch, Nina
AU - Aktas, Bahriye
AU - Banys-Paluchowski, Maggie
AU - Kolberg-Liedtke, Cornelia
AU - Wöckel, Achim
AU - Kolberg, Hans-Christian
AU - Harbeck, Nadia
AU - Stickeler, Elmar
AU - Tesch, Hans
AU - Hartkopf, Andreas D
N1 - The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ).
Publisher Copyright:
© 2023 The Author(s).
PY - 2023/3
Y1 - 2023/3
N2 - Large-scale study programs on CDK4/6 inhibitors, targeted therapies, and antibody-drug conjugates launched in recent years have yielded results from current studies which are now being published in journals and presented at international conferences. In this context, new results are available from the major CDK4/6 inhibitor studies. Also, an increasing amount of data is being published from large-scale genomic studies on efficacy and resistance mechanisms in patients treated with CDK4/6 inhibitors. These results now form the basis for further research plans to investigate combination therapies and treatment sequencing. Based on the latest published results, sacituzumab govitecan is now available as a second antibody-drug conjugate; this brings an advantage in terms of overall survival for patients with hormone receptor-positive (HRpos)/HER2-negative (HER2neg) breast cancer. In this review article, we summarize the latest developments and place them in context according to the current status of research.
AB - Large-scale study programs on CDK4/6 inhibitors, targeted therapies, and antibody-drug conjugates launched in recent years have yielded results from current studies which are now being published in journals and presented at international conferences. In this context, new results are available from the major CDK4/6 inhibitor studies. Also, an increasing amount of data is being published from large-scale genomic studies on efficacy and resistance mechanisms in patients treated with CDK4/6 inhibitors. These results now form the basis for further research plans to investigate combination therapies and treatment sequencing. Based on the latest published results, sacituzumab govitecan is now available as a second antibody-drug conjugate; this brings an advantage in terms of overall survival for patients with hormone receptor-positive (HRpos)/HER2-negative (HER2neg) breast cancer. In this review article, we summarize the latest developments and place them in context according to the current status of research.
UR - http://www.scopus.com/inward/record.url?scp=85150436628&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/00014038-f4bf-3658-bae7-58ef56a37ad7/
U2 - 10.1055/a-2018-9184
DO - 10.1055/a-2018-9184
M3 - Scientific review articles
C2 - 36908287
SN - 0016-5751
VL - 83
SP - 299
EP - 309
JO - Geburtshilfe und Frauenheilkunde
JF - Geburtshilfe und Frauenheilkunde
IS - 03
ER -
